These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2105373)

  • 1. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins.
    Vega GL; Krauss RM; Grundy SM
    J Intern Med; 1990 Feb; 227(2):81-94. PubMed ID: 2105373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome.
    Toto RD; Grundy SM; Vega GL
    Am J Nephrol; 2000; 20(1):12-7. PubMed ID: 10644862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
    Cuchel M; Schaefer EJ; Millar JS; Jones PJ; Dolnikowski GG; Vergani C; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):1910-7. PubMed ID: 9351353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus.
    Lee SJ; Sacks FM
    Am J Cardiol; 2003 Jul; 92(2):121-4. PubMed ID: 12860210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
    Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
    Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy.
    Aguilar-Salinas CA; Hugh P; Barrett R; Pulai J; Zhu XL; Schonfeld G
    Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):72-82. PubMed ID: 9012640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
    Tobert JA
    Circulation; 1987 Sep; 76(3):534-8. PubMed ID: 3113763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.
    Vega GL; East C; Grundy SM
    Atherosclerosis; 1988 Mar; 70(1-2):131-43. PubMed ID: 3162680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin.
    Contacos C; Barter PJ; Vrga L; Sullivan DR
    Atherosclerosis; 1998 Nov; 141(1):87-98. PubMed ID: 9863541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of the effectiveness of the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in hypercholesteremia].
    Schwartzkopff W; Bimmermann A; Schleicher J
    Arzneimittelforschung; 1990 Dec; 40(12):1322-7. PubMed ID: 2128866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
    Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV
    J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
    Aguilar-Salinas CA; Barrett PH; Kelber J; Delmez J; Schonfeld G
    J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two patterns of LDL metabolism in normotriglyceridemic patients with hypoalphalipoproteinemia.
    Vega GL; Grundy SM
    Arterioscler Thromb; 1993 Apr; 13(4):579-89. PubMed ID: 8466893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin.
    Arca M; Vega GL; Grundy SM
    JAMA; 1994 Feb; 271(6):453-9. PubMed ID: 8295321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of obesity on the metabolism of apolipoprotein B in humans.
    Egusa G; Beltz WF; Grundy SM; Howard BV
    J Clin Invest; 1985 Aug; 76(2):596-603. PubMed ID: 4031064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.
    Gaw A; Packard CJ; Lindsay GM; Griffin BA; Caslake MJ; Lorimer AR; Shepherd J
    J Lipid Res; 1995 Jan; 36(1):158-71. PubMed ID: 7706941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG
    J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.